- Haben Sie Fragen?
- Tel. 01 263 35 58
- praxis@allgemeinmedizin1220.at
- 1220 Wien, Schüttaustrasse 20-40/9/3+4 | Urlaub: 14.3. - 29.3.2026
Literatur/Links
- Home
- Literatur/Links
Inhaltsverzeichnis
Allgemein
Lehrbuch
Kirsten R. Müller-Vahl/Franjo Grotenhermen; Cannabis und Cannabinoide; Medizinisch Wissenschaftliche Verlagsgesellschaft; 2020
Fachinformationen/cannabisbasierte Medikamente
Fachinformation Sativex(R),(Nabiximols)
https://www.cannabis-med.org/german/sativex.pdf
Fachinformation Canemes(R),(Nabilon)
Schmerz/Kopfschmerz
Überall MA. A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain. J Pain Res. 2020 Feb 14;13:399-410. doi: 10.2147/JPR.S240011. PMID: 32104061; PMCID: PMC7027889.
https://pubmed.ncbi.nlm.nih.gov/32104061/
Ueberall MA, Essner U, Mueller-Schwefe GH. Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry. J Pain Res. 2019 May 20;12:1577-1604. doi: 10.2147/JPR.S192174. PMID: 31190969; PMCID: PMC6535492.
https://pubmed.ncbi.nlm.nih.gov/31190969/
Cuttler C, Spradlin A, Cleveland MJ, Craft RM. Short- and Long-Term Effects of Cannabis on Headache and Migraine. J Pain. 2020 May-Jun;21(5-6):722-730. doi: 10.1016/j.jpain.2019.11.001. Epub 2019 Nov 9. PMID: 31715263.
https://pubmed.ncbi.nlm.nih.gov/31715263/
Baron EP. Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science. Headache. 2018 Jul;58(7):1139-1186. doi: 10.1111/head.13345. PMID: 30152161.
https://pubmed.ncbi.nlm.nih.gov/30152161/
Baron EP, Lucas P, Eades J, Hogue O. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. J Headache Pain. 2018 May 24;19(1):37. doi: 10.1186/s10194-018-0862-2. PMID: 29797104; PMCID: PMC5968020.
https://pubmed.ncbi.nlm.nih.gov/29797104/
Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther. 2007 Sep;29(9):2068-79. doi: 10.1016/j.clinthera.2007.09.013. PMID: 18035205.
https://pubmed.ncbi.nlm.nih.gov/18035205/
Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010 Feb;39(2):167-79. doi: 10.1016/j.jpainsymman.2009.06.008. Epub 2009 Nov 5. PMID: 19896326.
https://pubmed.ncbi.nlm.nih.gov/19896326/
Übelkeit/ Erbrechen/ Gewichtsabnahme
Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev. 2015 Nov 12;2015(11):CD009464. doi: 10.1002/14651858.CD009464.pub2. PMID: 26561338; PMCID: PMC6931414.
https://pubmed.ncbi.nlm.nih.gov/26561338/
Mortimer TL, Mabin T, Engelbrecht AM. Cannabinoids: the lows and the highs of chemotherapy-induced nausea and vomiting. Future Oncol. 2019 Mar;15(9):1035-1049. doi: 10.2217/fon-2018-0530. Epub 2019 Feb 5. PMID: 30720344.
https://pubmed.ncbi.nlm.nih.gov/30720344/
Tourette Syndrom und andere Tic Störungen
Müller-Vahl KR, Schneider U, Koblenz A, Jöbges M, Kolbe H, Daldrup T, Emrich HM. Treatment of Tourette’s syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry. 2002 Mar;35(2):57-61. doi: 10.1055/s-2002-25028. PMID: 11951146.
https://pubmed.ncbi.nlm.nih.gov/11951146/
Müller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, Emrich HM. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry. 2003 Apr;64(4):459-65. doi: 10.4088/jcp.v64n0417. PMID: 12716250.
https://pubmed.ncbi.nlm.nih.gov/12716250/
Müller-Vahl KR, Prevedel H, Theloe K, Kolbe H, Emrich HM, Schneider U. Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. Neuropsychopharmacology. 2003 Feb;28(2):384-8. doi: 10.1038/sj.npp.1300047. PMID: 12589392.
https://pubmed.ncbi.nlm.nih.gov/12589392/
Müller-Vahl KR. Treatment of Tourette syndrome with cannabinoids. Behav Neurol. 2013;27(1):119-24. doi: 10.3233/BEN-120276. PMID: 23187140; PMCID: PMC5215298.
https://pubmed.ncbi.nlm.nih.gov/23187140/
Milosev LM, Psathakis N, Szejko N, Jakubovski E, Müller-Vahl KR. Treatment of Gilles de la Tourette Syndrome with Cannabis-Based Medicine: Results from a Retrospective Analysis and Online Survey. Cannabis Cannabinoid Res. 2019 Dec 9;4(4):265-274. doi: 10.1089/can.2018.0050. PMID: 31872061; PMCID: PMC6922065.
https://pubmed.ncbi.nlm.nih.gov/31872061/
Müller-Vahl KR, Bindila L, Lutz B, Musshoff F, Skripuletz T, Baumgaertel C, Sühs KW. Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome. Neuropsychopharmacology. 2020 Jul;45(8):1323-1329. doi: 10.1038/s41386-020-0671-6. Epub 2020 Apr 9. PMID: 32272483; PMCID: PMC7297729.
https://pubmed.ncbi.nlm.nih.gov/32272483/
Artukoglu BB, Bloch MH. The Potential of Cannabinoid-Based Treatments in Tourette Syndrome. CNS Drugs. 2019 May;33(5):417-430. doi: 10.1007/s40263-019-00627-1. PMID: 30977108.
https://pubmed.ncbi.nlm.nih.gov/30977108/
Schlafstörungen
Babson KA, Sottile J, Morabito D. Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Curr Psychiatry Rep. 2017 Apr;19(4):23. doi: 10.1007/s11920-017-0775-9. PMID: 28349316.
https://pubmed.ncbi.nlm.nih.gov/28349316/
Belendiuk KA, Babson KA, Vandrey R, Bonn-Miller MO. Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users. Addict Behav. 2015 Nov;50:178-81. doi: 10.1016/j.addbeh.2015.06.032. Epub 2015 Jun 23. PMID: 26151582.
https://pubmed.ncbi.nlm.nih.gov/26151582/
Zwangserkrankung
Mauzay D, LaFrance EM, Cuttler C. Acute Effects of Cannabis on Symptoms of Obsessive-Compulsive Disorder. J Affect Disord. 2021 Jan 15;279:158-163. doi: 10.1016/j.jad.2020.09.124. Epub 2020 Oct 6. PMID: 33049434.
https://pubmed.ncbi.nlm.nih.gov/33049434/
Szejko N, Fremer C, Müller-Vahl KR. Cannabis Improves Obsessive-Compulsive Disorder-Case Report and Review of the Literature. Front Psychiatry. 2020 Jul 21;11:681. doi: 10.3389/fpsyt.2020.00681. PMID: 32848902; PMCID: PMC7396551.
https://pubmed.ncbi.nlm.nih.gov/32848902/
Angsterkrankung
Crippa JA, Zuardi AW, Martín-Santos R, Bhattacharyya S, Atakan Z, McGuire P, Fusar-Poli P. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol. 2009 Oct;24(7):515-23. doi: 10.1002/hup.1048. PMID: 19693792.
https://pubmed.ncbi.nlm.nih.gov/19693792/
Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015 Oct;12(4):825-36. doi: 10.1007/s13311-015-0387-1. PMID: 26341731; PMCID: PMC4604171.
https://pubmed.ncbi.nlm.nih.gov/26341731/
Posttraumatische Belastungsstörung
Orsolini L, Chiappini S, Volpe U, Berardis D, Latini R, Papanti GD, Corkery AJM. Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review. Medicina (Kaunas). 2019 Aug 23;55(9):525. doi: 10.3390/medicina55090525. PMID: 31450833; PMCID: PMC6780141.
https://pubmed.ncbi.nlm.nih.gov/31450833/
Reizdarmsyndrom
Quezada SM, Cross RK. Cannabis and Turmeric as Complementary Treatments for IBD and Other Digestive Diseases. Curr Gastroenterol Rep. 2019 Jan 11;21(2):2. doi: 10.1007/s11894-019-0670-0. PMID: 30635796.
https://pubmed.ncbi.nlm.nih.gov/30635796/
Depression
Feingold D, Weinstein A. Cannabis and Depression. Adv Exp Med Biol. 2021;1264:67-80. doi: 10.1007/978-3-030-57369-0_5. PMID: 33332004.
https://pubmed.ncbi.nlm.nih.gov/33332004/
Neurodegenerative Erkrankungen
Peball M, Krismer F, Knaus HG, Djamshidian A, Werkmann M, Carbone F, Ellmerer P, Heim B, Marini K, Valent D, Goebel G, Ulmer H, Stockner H, Wenning GK, Stolz R, Krejcy K, Poewe W, Seppi K; Collaborators of the Parkinson’s Disease Working Group Innsbruck. Non-Motor Symptoms in Parkinson’s Disease are Reduced by Nabilone. Ann Neurol. 2020 Oct;88(4):712-722. doi: 10.1002/ana.25864. Epub 2020 Aug 31. PMID: 32757413; PMCID: PMC7540547.
https://pubmed.ncbi.nlm.nih.gov/32757413/